The FDA converted Ibrance to regular FDA approval and approved a supplemental New Drug Application for the drug, broadening its range of antihormonal therapy.
In a recent study, researchers examined whether a compound found in soy, isoflavone, could potentially reduce all-cause mortality risk in breast cancer survivors.
In a recent study, researchers sought to determine if cholesterol lowering medication effected survival and recurrence outcomes in patients with breast cancer.
A new phase 3 trial evaluates whether trastuzumab deruxtecan (T-DXd) can improve invasive disease-free survival compared with trastuzumab emtansine (T-DM1) in patients with residual HER2-positive early...
